相关实验视频

Updated: Mar 2, 2026

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

基于Inavolisib的组合疗法用于治疗PIK3CAM突变HR+/HER2-乳腺癌:概述

Sushmita Bhatia¹, Neha Bhatia¹, Suresh Thareja¹

¹Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, Punjab 151401, India.

Mini reviews in medicinal chemistry

|March 1, 2026

概括

作为PI3Kα抑制剂的伊纳沃利西布在PIK3CA突变乳腺癌中表现有前途. 这种下一代药物提供了更好的疗效和耐受性,针对关键的癌症途径.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

PI3K/AKT/mTOR通路对于乳腺癌的进展和治疗耐药性至关重要.
需要选择性PI3Kα抑制,以提高HR+/HER2-乳腺癌的耐受性和疗效.
PIK3CA突变驱动癌症生长,是新疗法的目标.

研究的目的:

为提供关于新型PI3Kα抑制剂inavolisib的全面审查.
讨论其临床前疗效,作用机制和组合疗法的潜力.
探索个人化瘤学中耐药性机制和未来的方向.

主要方法:

对伊纳沃利西布的结构和药理动力学的临床前数据的审查.
在体内抗瘤活性和作用机制研究的分析.
评估组合策略和新出现的阻力模式.

主要成果:

伊纳沃利西布表现出对PI3Kα的增强效能和选择性.
与较旧的抑制剂相比,它表现出优异的抗瘤活性,减少了目标外效应.
临床前研究支持其在内分泌耐药性的组合疗法中的潜力.

结论:

伊纳沃利西布是治疗PIK3CA突变乳腺癌的新一代疗法.
它对PI3Kα的选择性提供了治疗优势和个性化瘤学的潜力.
对组合策略和抵抗缓解的进一步研究是有必要的.

关键词:

这是不可思议的.这是一种PI3Kα抑制剂.内分泌耐药性的内分泌抵抗.富尔维斯特兰特 (Fulvestrant) 是一个充满活力的项目.这是palbocicliblib.药理动力学药理动力学有针对性的治疗.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...